Please login to the form below

Not currently logged in
Email:
Password:

Syncona

This page shows the latest Syncona news and features for those working in and with pharma, biotech and healthcare.

$450m diagnostics sale will fuel more Syncona biotech funding

$450m diagnostics sale will fuel more Syncona biotech funding

Radiopharmaceuticals firm sold to Braco Imaging. Syncona has sold off its innovative diagnostics company Blue Earth Imaging to Bracco Imaging for $450m (£354.3m). ... owner will continue to develop the business through its next chapter,” said Martin

Latest news

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    After a merger with fellow Syncona stablemate Orbit, Soraya has taken on the R&D lead role, charged with developing and eventually gaining approval for its lead investigational gene therapy, GT005

  • European venture funding for the life science sector European venture funding for the life science sector

    New funds such as Oxford Sciences Innovation, Syncona (which listed at the start of the year and consequently increased its deployment capital) are likely to reinforce this trend going forward. ... The recent flotation of Syncona’s Nightstar

  • Pharma deals during January 2013 Pharma deals during January 2013

    in this vein this year, the Wellcome Trust announced the investment of $200m initial capital into Syncona Partners LLP a new evergreen investment company. Syncona will make investments across healthcare – device, ... Acquisition. Contraception

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    team. Chris Hollowood, chairman of the board and chief investment office at Syncona, said: “We are extremely pleased to appoint Soraya and look forward to her leadership and extensive gene therapy

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Chris Hollowood, chairman of Freeline Therapeutics and chief investment officer of Syncona, said: “Anne is an extremely accomplished executive with extensive experience in building and leading teams and developing haematology and

  • Edward Hodgkin elected chair of UK biotech association Edward Hodgkin elected chair of UK biotech association

    Hodgkin is currently a partner at the Wellcome Trust's independent subsidiary Syncona Partners, where his role is to create and lead new life science ventures.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...